04.24.24
Beiersdorf has entered a multi-year strategic partnership with Rubedo Life Sciences, a biotechnology company that specializes in cellular senescence and anti-aging research. Through this partnership, the two companies are developing skincare products that address the effects of cellular aging.
This partnership explores the compounds derived from Rubedo's extensive research programs, specifically targeting cellular senescence. Beiersdorf will conduct in vitro and in silico studies and will conduct rigorous assessments of identified compounds from Rubedo.
Senescent cells accumulate with age and may contribute to age-related skin changes and pathologies. Compounds will be sourced from Rubedo's topical dermatology program, which has senolytic and anti-inflammatory properties.
The collaborative effort will culminate in in vivo human studies, aimed at validating the efficacy of the selected compounds in cosmetic skin care formulations.
Rubedo's approach to compound development, combined with Beiersdorf's global brand platforms, is “poised to set new standards in anti-aging skincare and develop new solutions for the multi-billion face care market,” the companies said.
Additionally, Beiersdorf joins Rubedo as a strategic investor, having participated in its recent Series A financing round through its Oscar & Paul Corporate Venture Capital Fund.
“Our mission is to define the future of skincare through breakthrough innovation,” commented Vincent Warnery, Beiersdorf CEO. “By partnering with Rubedo and combining cutting-edge expertise from both sides, we aim to redefine the standards in anti-age skincare.”
Marco Quarta, CEO of Rubedo Life Sciences said, “By combining Rubedo's expertise in cellular senescence with Beiersdorf's complementary expertise in skincare innovation, this partnership may revolutionize the landscape of skin care products, offering consumers new solutions that treat cellular aging for healthy and youthful-looking skin.”
Nivea Redesigns Packaging to Meet Beiersdorf's 2025 Sustainability Goals
SkinCeuticals' New Serum Triggers Cell Turnover
This partnership explores the compounds derived from Rubedo's extensive research programs, specifically targeting cellular senescence. Beiersdorf will conduct in vitro and in silico studies and will conduct rigorous assessments of identified compounds from Rubedo.
Senescent cells accumulate with age and may contribute to age-related skin changes and pathologies. Compounds will be sourced from Rubedo's topical dermatology program, which has senolytic and anti-inflammatory properties.
The collaborative effort will culminate in in vivo human studies, aimed at validating the efficacy of the selected compounds in cosmetic skin care formulations.
Rubedo's approach to compound development, combined with Beiersdorf's global brand platforms, is “poised to set new standards in anti-aging skincare and develop new solutions for the multi-billion face care market,” the companies said.
Additionally, Beiersdorf joins Rubedo as a strategic investor, having participated in its recent Series A financing round through its Oscar & Paul Corporate Venture Capital Fund.
“Our mission is to define the future of skincare through breakthrough innovation,” commented Vincent Warnery, Beiersdorf CEO. “By partnering with Rubedo and combining cutting-edge expertise from both sides, we aim to redefine the standards in anti-age skincare.”
Marco Quarta, CEO of Rubedo Life Sciences said, “By combining Rubedo's expertise in cellular senescence with Beiersdorf's complementary expertise in skincare innovation, this partnership may revolutionize the landscape of skin care products, offering consumers new solutions that treat cellular aging for healthy and youthful-looking skin.”
Read Next
Beiersdorf Reports Strong First Quarter of 2024Nivea Redesigns Packaging to Meet Beiersdorf's 2025 Sustainability Goals
SkinCeuticals' New Serum Triggers Cell Turnover